Literature DB >> 23770852

ERα, SKP2 and E2F-1 form a feed forward loop driving late ERα targets and G1 cell cycle progression.

W Zhou1, S Srinivasan1, Z Nawaz1, J M Slingerland2.   

Abstract

Estrogen triggers transactivation coupled estrogen receptor α (ERα) proteolysis, but mechanisms thereof remain obscure. Present data link estrogen:ERα-driven transcription with cell cycle progression. Although liganded ERα induces many genes within 1-4 h, gene activation after 6 h is thought to be indirect. Here, we identify SKP2 as a late-acting coactivator that drives ERα targets to promote G1-to-S progression. Data support a model in which estrogen-activated cyclin E-CDK2 binds and phosphorylates ERαS341, to prime ERα-SCF(SKP2) binding via SKP2-L248QTLL252 in late G1. SKP2 activates ERα ubiquitylation and proteolysis. Putative late ERα targets were identified by expression profiling. SKP2 knockdown attenuated E2F-1 and BLM induction. SKP2 overexpression, but not coactivator motif mutant SKP2-L248QTAA252, enhanced estrogen-induced E2F-1 and BLM expression. SKP2 knockdown impaired estrogen-stimulated ERα, SKP2, SRC3 and RNA polymerase II recruitment to E2F-1 and BLM promoters. This work not only identifies these late-activated genes as bona fide ERα targets but describes a novel mechanism for their periodic activation. SKP2 serves as dual ERα E3 ligase/coactivator for late-activated target genes, revealing a novel mechanism whereby ERα/SCF(SKP2) transactivation of E2F-1 feeds forward to drive G1-to-S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23770852     DOI: 10.1038/onc.2013.197

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy.

Authors:  Wen Zhou; Joyce M Slingerland
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

2.  Beta-catenin and estrogen signaling collaborate to drive cyclin D1 expression in developing mouse prostate.

Authors:  William A Mulligan; Kyle A Wegner; Kimberly P Keil; Vatsal Mehta; M Mark Taketo; Chad M Vezina
Journal:  Differentiation       Date:  2016-12-02       Impact factor: 3.880

3.  Phosphorylation of Farnesoid X Receptor at Serine 154 Links Ligand Activation With Degradation.

Authors:  Takuyu Hashiguchi; Shingo Arakawa; Shogo Takahashi; Frank J Gonzalez; Tatsuya Sueyoshi; Masahiko Negishi
Journal:  Mol Endocrinol       Date:  2016-08-29

4.  Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.

Authors:  Elin Karlsson; Ivana Magić; Josefine Bostner; Christine Dyrager; Fredrik Lysholm; Anna-Lotta Hallbeck; Olle Stål; Patrik Lundström
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

5.  Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells.

Authors:  Y-J Liao; H-Y Bai; Z-H Li; J Zou; J-W Chen; F Zheng; J-X Zhang; S-J Mai; M-S Zeng; H-D Sun; J-X Pu; D Xie
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

6.  A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer.

Authors:  Lon W R Fong; Jangsoon Lee; Hui-Kuan Lin; Naoto T Ueno; Shuxing Zhang
Journal:  Sci Rep       Date:  2022-02-15       Impact factor: 4.379

7.  Estrogen as Jekyll and Hyde: regulation of cell death.

Authors:  Wen Zhou; Xiaoxia Zhu
Journal:  F1000Res       Date:  2014-07-11

Review 8.  Regulation of steroid hormone receptors and coregulators during the cell cycle highlights potential novel function in addition to roles as transcription factors.

Authors:  Yingfeng Zheng; Leigh C Murphy
Journal:  Nucl Recept Signal       Date:  2016-01-13

Review 9.  Polyubiquitination inhibition of estrogen receptor alpha and its implications in breast cancer.

Authors:  Angeles C Tecalco-Cruz; Josué O Ramírez-Jarquín
Journal:  World J Clin Oncol       Date:  2018-08-13

Review 10.  Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.

Authors:  Troy B Schedin; Virginia F Borges; Elena Shagisultanova
Journal:  Int J Breast Cancer       Date:  2018-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.